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Very little research has been conducted with older adult samples of individuals with 
multiple sclerosis (MS). In particular, it is not clear whether the cognitive profile of older adult 
MS patients follows the same patterns observed in younger MS patients. At the level of an 
individual patient, possible etiologies for changes in cognition include worsening MS, normal 
consequences of aging, the development of a comorbid condition, or an interaction of these 
possibilities. This study compared the performance of MS (n = 64), amnestic mild cognitive 
impairment (aMCI; n = 58), and healthy control (n = 70) samples over the age of 60 on a 
neuropsychological testing battery. Older adult MS patients consistently performed better than 
aMCI patients and worse than controls. However, secondary progressive MS patients did not 
significantly differ from aMCI patients on any cognitive measure. Criteria for cognitive 
impairment were met by 20% of the MS sample. MS patients were most frequently impaired on 
tasks of processing speed and memory. Significant predictors of cognitive impairment were 
physical disability and disease duration. Overall, the cognitive profile of older adult MS patients 
is largely consistent with that of younger MS patients. However, differences in impairment 
between secondary progressive and primary progressive patients were not as distinct as 
previously reported in the literature. Additionally, disease duration was more strongly associated 
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COGNITION IN OLDER ADULT MS PATIENTS COMPARED TO HEALTHY CONTROLS 
AND aMCI PATIENTS 
Multiple sclerosis (MS) is an immune-mediated disease of the nervous system. It is a 
progressive condition characterized by worsening motor, sensory, and cognitive disability over 
time. Relatively recent advancements in the treatment of MS have resulted in an improved 
prognosis and life expectancy for patients (Finlayson, 2009). As a result, a new cohort of MS 
patients – that of older adults – has emerged. From a clinical and research perspective, it is 
important to consider the medical, psychosocial, and cognitive factors that may be unique to this 
subsample relative to the broader MS population. However, at this time, there is very little 
characterization of MS patients over the age of 60 within the research literature (Gray & Arnett, 
2014).  
One aspect of functioning that may be different between older adult and younger MS 
patients is that of cognitive performance. Forty-three to 70 percent of MS patients experience 
cognitive impairment at some point in their disease (Chiaravalloti & DeLuca, 2008). These 
symptoms typically appear early in the disease course and persist or worsen over time (Amato, 
Zipoli, & Portaccio, 2006). Currently, it is unclear whether the cognitive patterns observed in 
younger patients – such as affected domains, rates of impairment, or predictors of cognition – 
hold true in older adult patients.  
The purpose of the present study was to characterize the cognitive profile of a sample of 
older adult MS patients using a neuropsychological test battery. Performance on the battery was 
compared to healthy controls, as well as a clinical population of patients with amnestic mild 
cognitive impairment (aMCI). The aMCI group was selected for two reasons. First, this sample 
represents a patient group similar to MS in that individuals may experience documented 
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cognitive impairment in select domains, while their activities of daily living remain largely 
intact. Second, this sample is also of interest in the context of aging. It is possible that an older 
adult MS patient may present with concerns about cognition similar to those expressed by an 
individual diagnosed with aMCI; therefore, being able to differentiate between these groups may 
be important in a clinical context. Finally, in addition to between-group differences, patterns of 
cognitive performance and impairment were also explored within the MS sample and across MS 
subtypes.  
Aging and Multiple Sclerosis 
 In general, the topic of aging and MS is currently understudied within the field, and no 
clear picture exists of the lives of older adults with MS. It is estimated that approximately 9% of 
MS patients are older than 65 years, which is equal to 225,000-350,000 individuals worldwide 
(Awad & Stüve, 2010). Within the available literature, some discrepancies exist regarding life 
expectancy in MS. Many studies suggest MS can shorten the life span by 5 to 10 years; however, 
other work indicates individuals with MS can live as long as their peers (Finlayson, 2009). Over 
the last 40 years, mean survival time has improved, which is consistent both with trends in the 
general population as well as within populations of disabled individuals (Finlayson, 2009). In 
addition to these general trends, a relatively recent change that has specifically affected those 
with MS is the introduction of disease-modifying treatments (DMT). These treatments help to 
reduce disease pathology and, to some degree, slow disease progression (Freedman, 2005). The 
first DMT was approved by the Food and Drug Administration for use in the United States in 
1993. Thus, the relative newness of this sub-population may account for the limited research thus 
far undertaken with aging MS patients.  
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What is known about MS and older adulthood has been summarized in a number of 
recent reviews. Stern (2005) and Awad and Stüve (2010) discussed the epidemiology of MS in 
old age as well as the clinical, pathological, and neuroimaging presentations of older adult MS 
patients. Other research has focused on psychosocial factors, including discussions of activity 
limitations, the subjective experience of aging with MS, and the family and professional care 
needs of individuals with MS (Finlayson, 2009). The most recent review by Gray and Arnett 
(2014) sought to supplement areas not previously discussed. They reported on cognitive, 
emotional, and neuropathological variables associated with old age and MS. Overall, there is a 
burgeoning interest regarding the aging process within MS, as indicated by the recency of these 
reviews.  
Multiple Sclerosis and Cognition 
The novelty of this interest is reflected by the limited number of studies within the 
literature reporting on cognition in older adult MS patients. In fact, only three articles were 
identified that included patient samples with a mean age over 60 years old. Before considering 
these specific studies, it is helpful to understand the broader state of research in the field of 
cognition and MS. Additionally, because of the limited amount of research with older adults, the 
findings of longitudinal studies on cognition can also supplement our understanding of this 
growing MS sub-population.  
Cognitive Findings. Consistent with other MS symptoms, cognitive deficits are 
significantly heterogeneous across individual patients. For this reason, a variety of approaches 
have been developed to assess cognition in MS patients. Cognitive screening tools – either 
traditional neurological tests (e.g., Mini Mental Status Exam, MMSE) or single instruments 
demonstrated to be sensitive to MS (e.g., Symbol Digit Modalities Test, SDMT) – have generally 
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been viewed as insufficient in identifying patients with cognitive impairment (Aupperle, Beatty, 
Shelton, & Gontkovsky, 2002; Beatty, Goodkin, Hertsgaard, & Monson, 1990; DeLuca, Yates, 
Beale, & Morrow, 2014). Therefore, three MS-specific cognitive batteries have been developed 
over time. Rao’s Brief Repeatable Neuropsychological Battery (BRN-B) (Bever, Grattan, 
Panitch, & Johnson, 1995) assesses auditory and visual processing speed (i.e., Paced Auditory 
Serial Addition Task, PASAT; SDMT), verbal and visuospatial memory (i.e., Selective 
Reminding Task, 10/36 Spatial Recall Task), and verbal fluency (i.e., Controlled Oral Word 
Association Test). In 2002, a panel of researchers developed the Minimal Assessment of 
Cognitive Function in MS (MACFIMS), which added two additional cognitive domains for 
assessment: visuospatial perception (i.e., Judgement of Line Orientation) and executive function 
(i.e., Sorting subtest of the Delis-Kaplan Executive Function System; Benedict et al., 2002). The 
MACFIMS battery retained the use of the PASAT and SDMT, and modified the memory tasks to 
include the California Verbal Learning Test, 2nd Edition (CVLT2) and the Brief Visuospatial 
Memory Test-Revised (BVMT-R). The MACFIMS can take up to two hours to administer, so a 
recent effort has been made to develop a quicker, 15-minute battery. The Brief International 
Cognitive Assessment for Multiple Sclerosis (BiCAMS) battery consists only of the SDMT and 
immediate recall on verbal and visual memory tasks (i.e., CVLT2, BVMT; Langdon, et al., 
2012).  
Across assessment instruments and batteries, a general pattern of cognitive performance 
has emerged over the past few decades. The two most commonly affected abilities are those of 
processing speed and memory (see reviews: Chiaravalloti & DeLuca, 2008; DeLuca et al., 2014). 
Some studies report deficits in executive function, primarily as measured on tasks of verbal 
fluency; however, these impairments are observed at a lower frequency than those of processing 
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speed or memory (Chiaravalloti & DeLuca, 2008). Similarly, some studies report poor 
visuospatial perception and processing; however, more detailed analysis suggests these apparent 
higher order deficits might be better explained by slowed performance on speed-dependent tasks 
(Zakzanis, 2000). Simple attention, word naming, and general intelligence are broadly intact. 
With respect to memory, specific deficits have been reported in both recall and retrieval 
processes (Chiaravalloti & DeLuca, 2008; Guimarães & Sá, 2012). However, further 
investigation into poor recall on list learning tasks has suggested that MS cognitive deficits may 
be better described as deficits in acquisition rather than memory-related problems in storage or 
retrieval (DeLuca, Gaudino, Diamond, Christodoulou, & Engel, 1998; Demaree, Gaudino, 
DeLuca, & Ricker, 2000). When MS patients and healthy controls are trained to a specific 
criterion, MS patients require more repetitions to acquire new information; however, once 
encoded, MS patients have comparable free recall and recognition as healthy controls (DeLuca et 
al.; Demaree et al.; Diamond, DeLuca, Johnson, & Kelley, 1997). It has been suggested that this 
deficit in acquisition may be a result of MS patients’ slowed processing speed (Faglioni, 
Bertolani, Botti, & Merelli, 2000). Therefore, the two cognitive deficits most commonly 
observed in MS patients are that of slowed processing speed and poor acquisition of new 
information. 
A significant body of research has also investigated various factors and predictors that 
may be associated with cognitive dysfunction. Impairment can be seen regardless of disease 
duration, and only moderate associations have been found with physical disability (Chiaravalloti 
& DeLuca, 2008). Disease subtype, however, is relevant. More severe cognitive deficits have 
been reported in progressive subtypes relative to relapsing remitting (RRMS) patients. A meta-
analysis also reported different patterns in impairment across subtypes, with progressive patients 
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experiencing more frontal-executive deficits, and relapsing remitting patients being characterized 
more by deficits on tests of memory function (Zakzanis, 2000). Among the progressive subtypes, 
some studies report a higher frequency of cognitive impairment in secondary progressive 
(SPMS) relative to primary progressive (PPMS) patients; however, others studies find no 
difference (DeLuca et al., 2014). Depression has also been demonstrated to be significantly 
associated with cognitive functioning in MS patients (Chiaravalloti & DeLuca, 2008). The 
lifetime prevalence of depression in MS nears 50%, which is approximately three times the rate 
of the general population (Feinstein, 2011) Therefore, it is recommended that depression is 
assessed in studies of cognition. Finally, a growing interest in the field is identification of 
pathological correlates of cognitive impairment. Cortical, deep grey matter, and white matter 
structures are all affected by MS pathology. Lesion load, whole brain atrophy, and volume 
changes in specific structures have all been linked to cognitive impairment (DeLuca et al., 2014). 
However, at this time, the link between MS pathology and cognition remains poorly understood.  
Cognitive Profile of Older Adult MS Patients. While there is generally accepted 
knowledge regarding patterns of cognitive performance in MS as well as significant factors that 
affect cognition, it is not yet clear whether these patterns persist as patients age. Only three 
identified studies have begun to address this question. The first of these studies focused 
specifically on processing speed across the lifespan in MS patients (Bodling, Denney, & Lynch, 
2009). The authors analyzed data from five previously published studies investigating 
information processing speed, as assessed by a computerized Stroop task. The researchers 
divided their patient and healthy control samples into five age cohorts and conducted an 
ANOVA to identify whether there were main effects for group (patients; controls) or age. 
Significant main effects were found for both group and age, such that MS patients were slower 
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than healthy controls, and older individuals were slower than younger. The researchers also 
hypothesized a significant interaction, such that group differences in processing speed would 
become greater as MS patients aged. They cited theoretical discussions in the literature regarding 
observed similarities in the cognitive profiles of MS patients and healthy aging adults as well as 
the hypothesis that MS might involve an acceleration of the normal aging process with respect to 
cognitive variables. However, within their sample (MS: n = 245; Controls: n = 188), no 
significant interaction was found. Possible explanations included the use of only a single 
measure of processing speed, a highly educated sample with a potentially greater cognitive 
reserve than representative of the population, and a small sample within the oldest cohort aged 
59 and older (MS: n = 18; Controls: n = 16). The authors suggested that further research is 
needed to better understand the relationship among MS disease trajectories and the aging 
process, and they particularly encouraged future investigators to not rule out the possibility of an 
interaction between these processes. 
The second study identified used a cross-sectional, population-based design. Individuals 
living in Oslo, Norway, and diagnosed between the years of 1940 and 1980 were recruited from 
a comprehensive patient registry (Smestad, Sandvik, Landrø, & Celius, 2010). Participants 
completed a testing battery assessing psychomotor speed, attention, learning/memory, and 
executive function. Ages ranged from 45 to 81 (M = 61), with an average disease duration of 
34.5 years. In at least two of four cognitive domains, individuals needed to score 1.5 standard 
deviations (SD) below a normative mean on at least one subtest in order to be labeled as 
cognitively impaired. Of the sample completing neuropsychological testing (n = 84), 48% met 
criteria for cognitive impairment, with the typical pattern involving moderate impairment of 
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information processing speed, attention, and memory. The investigators concluded that after 30 
years of MS, about half of patients will experience reduced cognitive functioning. 
A third study focused on the possibility of comorbid memory conditions in older adult 
MS patients (Müller et al., 2013). The researchers sought to identify which neuropsychological 
tasks would best differentiate a sample of SPMS patients (n = 40; M = 60.78 years) from aMCI 
(n = 40; M = 61.05 years) and healthy control samples (n = 40; M = 60.13 years). The results 
indicated that across all instruments, healthy controls performed significantly better than both 
patient groups. More interestingly, no significant differences were observed between SPMS and 
aMCI patients on any task, except recognition of a word list after a delayed recall. On this task, 
aMCI patients were significantly worse than SPMS patients, whose performance was equal to 
that of healthy controls. The ability of SPMS patients to perform better on recognition tasks 
compared to free recall is consistent with the broader MS literature describing impairments in 
acquisition but not memory storage. Also consistent with the larger literature was the authors’ 
conclusions–based on correlations between memory performance and other test variables–that 
poor recall may be due to impairment in executive function and poor processing speed (Müller et 
al., 2013).  
Longitudinal Findings. In light of the limited research on cognition in older adult MS 
patients, an alternative source of information is longitudinal trends in cognitive changes over the 
course of MS. Most longitudinal studies of cognition in MS have relatively brief (i.e., two to 
three year) follow-up periods. Only six published studies have investigated cognitive changes in 
MS patients for a period of time longer than five years, with follow-up periods ranging from 
seven (Haase et al., 2004) to 18 years (Strober, Rao, Lee, Fischer, & Rudick, 2014). All 
longitudinal studies observed cognitive deterioration in MS patients, though there was substantial 
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variation across studies in the degree of deterioration observed. Reported rates of the percentage 
of a sample shifting from an intact cognitive profile to an impaired profile ranged from 5% 
(Schwid, Goodman, Weinstein, McDermoot, & Johnson, 2007) to 30% (Amato, Ponziani, 
Siracusa, & Scorbi, 2001) over a 10-year period. Other studies reported an 18% shift over 18 
years (Strober et al., 2014) and a 16% change over eight years (Bergendal, Fredrikson, & 
Almkvist, 2007). One challenge in making comparisons across these studies is that impairment 
was operationally defined differently within each study. Impairment was sometimes relative to a 
control group; while at other times, it was relative to a normative sample. The degree of required 
deviation from the comparative sample also varied across studies (i.e., 0.5 SDs to 2.0 SDs). 
However, while there are some inconsistencies and limitations to the existing literature, a 
consistent finding across all studies is that cognitive abilities decline over time.  
The specific cognitive abilities that change over time is also somewhat variable across 
studies. Cognitive domains with reported declines include processing speed/attention (Schwid et 
al., 2007; Strober et al., 2014), visuospatial processing (Haase et al., 2004; Strober et al.), motor 
function (Bergendal et al., 2007), and executive function (Strober et al). Of the longer 
longitudinal studies, four out of five studies observed deterioration over time and significant 
impairment in either verbal memory (Amato, Ponziani et al., 2001; Piras et al., 2003; Strober et 
al.) or visual memory (Amato, Ponziani et al.; Bergendal et al.; Piras et al.). Consistent with 
cross sectional studies, intelligence and linguistic abilities appear to be largely preserved over 
time (Haase et al., Bergendal et al., Piras et al., Strober et al.). Additionally, the observed 
declines in memory and processing speed are consistent with the few studies conducted with 
older adult MS patients (Bodling et al., 2009; Müller et al., 2013; Smestad et al., 2010). 
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One goal of many of the longitudinal studies involved identifying predictors of cognitive 
decline. Specifically, in light of the fact that many MS patients display cognitive impairment 
throughout their disease course, investigators have examined whether current cognitive status is 
related to later cognitive status. No research consensus exists, however. Some studies reported 
that patients classified as impaired worsen more rapidly than a sample classified as cognitively 
intact (Amato, Portaccio et al., 2010; Bergendal et al., 2007; Kujala, Portin, & Ruutianinen, 
1997). Other studies report the opposite – patients within an intact group demonstrate greater 
relative decline, while the impaired sample remains stable (Schwid et al. 2007; Strober et al., 
2014). Still others report no relationship between baseline and follow-up cognitive status, 
although these studies tend to have follow-up periods of less than five years (Denney, Lynch, & 
Parmenter, 2008; Huijbregts, Kalkers, de Sonneville, de Groot, & Polman, 2006). 
A challenge when interpreting this literature is that the first or baseline assessment occurs 
at a different average disease duration, age, and level of physical disability for each patient 
sample. Thus, each study is capturing only a small snapshot of change occurring over the 
lifespan and, therefore, describing a different portion of a broader picture. The lack of consensus 
on the significance of current cognitive status for later cognitive status indicates that this cannot 
be used as a reliable predictor to infer the cognitive profile of older adult patients. 
Multimorbidity in Older Adult MS Patients. Another important consideration when 
discussing cognition in older adult MS patients is the possibility of a comorbid condition 
contributing to symptoms. There is increasing recognition that the presence of multiple, co-
existing pathologies is a frequent occurrence in aging brains (Jellinger & Attems, 2014). Of 
particular concern within the cognitive domain is the development of a comorbid degenerative 
dementia in addition to MS. In general, the most common form of dementia is Alzheimer’s 
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disease (AD; Alzheimer’s Association, 2013). Estimates from two national studies of older 
adults suggest that one in nine individuals aged 65 years or older and one in three individuals 
over the age of 85 are diagnosed with AD (Alzheimer’s Association, 2013). Combined with the 
prevalence estimates of older adult MS patients, these statistics suggest anywhere from 25,000 to 
39,000 MS patients worldwide may have comorbid AD. This estimate does not take into account 
other possible etiologies of cognitive decline, such as alternative forms of dementia or vascular 
complications, which may also interact with MS.  
Two recent publications report evidence of comorbid MS and AD. A case series out of 
the Mayo Clinic described three cases of MS patients with comorbid AD, one identified 
postmortem and two identified premortem (Flanagan, Knopman, & Keegan, 2014). The first case 
involved a 56-year-old woman presenting with progressive dementia over seven years and an 
atypical MS course. Her autopsy confirmed MS pathology and also revealed severe AD 
pathology (Braak stage VI of VI). The other two cases involved diagnosis–and treatment–of MS 
and AD premortem. Diagnoses were arrived at via measurement of cerebrospinal fluid levels of 
tau and amyloid-β1-42 concentrations, as well as evidence of bilateral hypometabolism on FDG-
PET scans. One patient was treated with donepezil and memantine and self-reported mild 
improvement; the second individual was prescribed donepezil but continued to decline. Neither 
of these cases included autopsy confirmed diagnoses. Each, however, provides some measure of 
evidence for comorbid MS and AD.  
More robust evidence of comorbidity comes from an archival autopsy study of 45 MS 
cases (Dal Bianco et al., 2008). Of the sample, 22 were 65 years or younger (age range: 28-64) 
and 23 were over the age of 65 (age range: 66-85). Pathology was staged according to the 
Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) criteria and Braak stages. 
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Of the 45 MS cases, 16 individuals (all over the age of 64) demonstrated Alzheimer’s pathology 
and eight of those met CERAD criteria for probable AD. The incidence of AD pathology in MS 
patients was compared to a previously published non-selected autopsy population of 1,258 
patients in a Swiss geriatric hospital viewed as representative of “normal aging” (i.e., 
Giannakopoulous, Hof, Mottier, Michel, & Bouras, 1994). The rate of AD pathology in MS 
patients appeared consistent with normal aging before the age of 64 and moderately (but not 
significantly) greater in patients over the age of 64. The authors concluded that “in aged MS 
patients, a cognitive decline may not only be related to MS-specific lesions but also to 
concomitant age-related development of AD pathology” (Dal Bianco et al., p. 180).  
Evidence of documented comorbidity highlights the need to include other conditions in 
clinical differentials when MS patients report worsening cognition. Additionally, this supports 
the benefit within MS research of including other clinical samples in cognitive studies. Being 
able to directly compare clinical groups can inform our understanding of relative deficits. It can 
also, hopefully, facilitate clinical decision making when determining whether a patient’s reported 
complaints warrant further evaluation or not.  
Discussion. A number of challenges exist when trying to understand the cognitive profile 
of older adult MS patients. There is a scarcity of studies directly addressing this topic, and more 
indirect routes of estimating cognitive abilities within this population have limitations, including 
wide variation in the clinical characteristics of patient samples, the definitions of impairment, 
and the cognitive domains selected for evaluation. Practical obstacles to the direct assessment of 
cognitive abilities in older adult MS patients may also exist. Greater age is often related to longer 
disease durations, which in turn, is related to greater levels of physical disability (Beatty et al., 
1990). Physical impairment may interfere with the ability to complete neuropsychological 
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batteries, particularly speeded tasks. For example, in Smestad and colleagues’ (2010) population-
based study of older MS patients, 32% of eligible patients declined to participate in cognitive 
testing. Attrition analyses indicated that these individuals were significantly older than those 
assessed (mean age 64.4 years vs. 60.6 years) and had a higher mean Expanded Disability Status 
Scale (EDSS) score (6.8 vs. 5.0). The absence of information from the most disabled individuals 
likely skews the collected data. 
Theoretical challenges also exist when trying to understand the underlying cause or 
causes of observed deficits in older adults. Possible attributions include worsening MS 
pathology, the effects of normal aging, the development of a comorbid cognitive disorder 
associated with aging, or an interaction of these possibilities. Various hypotheses exist as to how 
MS disease processes might interact with normal aging processes. For example, slowed 
processing speed is a widely recognized consequence of MS. However, reduced speed of 
processing is also associated with aging (Salthouse, 1992). Thus far, it is unclear how these 
parallel processes might intersect in older adult patients (Bodling et al., 2009; Kail, 1997). 
Similarly, at a neuropathological level, MRI lesion load has been associated with cognition in 
MS patients (Amato et al., 2006; Chiaravalloti & DeLuca, 2008). Specifically, MRI images in 
MS patients are characterized by subcortical hyperintense lesions in T2-weighted images. 
However, MRIs in older adults also show subcortical white matter hyperintensities that increase 
at a rate of 5% to 9% per year (Stern, 2005). Therefore, when studying older adults with MS, it 
remains unclear whether observed patterns in cognition or neuropathology should be viewed as 






The present study adds to the existing literature by investigating cognitive performance 
across three MS subtypes using a sample that has an older mean age than what is currently 
described in the literature. The performance of MS patients on a neuropsychological testing 
battery is compared to that of healthy controls and an aMCI patient sample. The study addresses 
four main aims and related hypotheses.  
Aim 1. We sought to characterize the cognitive profile of a sample of older adult MS patients 
using a neuropsychological testing battery that assesses attention, processing speed, executive 
function, memory, language, and visuospatial domains. Relative to other cognitive domains, it 
was hypothesized that MS patients would demonstrate the greatest impairment on tests of 
processing speed, followed by tests of memory. Additionally, we sought to explore differences 
across subtypes. We hypothesized that among the three subtypes, secondary progressive patients 
would demonstrate the highest degree of cognitive impairment. Finally, demographic and 
clinical characteristics that may be significant predictors of cognitive impairment were also 
explored. 
Aim 2. We sought to compare the cognitive performance of MS patients to a sample of 
healthy older adults. It was anticipated that MS patients would have significantly slower 
processing speed than controls, as demonstrated on the Digit-Symbol, Trails A, and Stroop tasks. 
It was also expected that MS patients would demonstrate impaired performance on a list learning 
task (i.e., Free & Cued Selective Reminding Test, FCSRT) and identify fewer items on the free 
recall trials than healthy controls.  
Aim 3. We sought to compare the cognitive performance of MS patients to a sample of 
aMCI patients. Amnestic MCI typically involves impaired memory function, while other 
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cognitive abilities remain broadly intact (Petersen et al., 2001). The specific pattern of memory 
performance typically involves deficits in free recall and delayed recall (Chen et al., 2000; Tabert 
et al., 2006). Additionally, mild deficits have been observed in verbal fluency, object naming, 
psychomotor speed, visuospatial processing, and attention (Tabert et al., 2006). It was 
hypothesized that MS patients would differ from aMCI patients on memory tasks. Specifically, 
on the FCSRT, MS patients would show a greater benefit from repetition and cued prompts, such 
that total free recall and overall accuracy will be better than aMCI patients. Additionally, we 
hypothesized that MS patients would perform significantly better than aMCI patients on 
language tasks.  
Aim 4. Finally, we sought to identify the cognitive variables that best illustrated 
differences between the MS and aMCI patient samples. It was anticipated that performance on 
the FCSRT would best characterize this difference.  
Method 
Participants 
Patients between the ages of 60 and 80 who met the revised McDonald criteria for MS 
(Polman, et al., 2005) were recruited from the University of Kansas Medical Center in Kansas 
City, KS. All patients were under the care of the same neurologist (S. G. L.) and had a diagnosis 
of relapsing remitting, secondary progressive, or primary progressive MS of at least one year 
duration. Patients were excluded from participation on the basis of any of the following: relapse 
within the past three months; neurological disorder other than MS; history of drug or alcohol 
abuse; severe visual impairment or no color vision; impairment in the use of their dominant 
hand; severe cognitive or psychiatric impairment of sufficient magnitude to interfere with the 
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ability to comprehend testing instructions or provide informed consent; or less than a high school 
education.  
 The remaining sample was extracted from archival data collected through the University 
of Kansas Alzheimer’s Disease Center (ADC). Individuals were self-referred to the ADC to 
participate in longitudinal research on cognition and aging. Individuals participated in 
neuropsychological testing and a Clinical Dementia Rating interview (CDR: Morris, 1993) 
annually. Based on the results, participants were classified into disease groups via consensus 
among a neurologist, neuropsychologist, and nurse clinician. A patient sample classified as 
aMCI with a CDR of 0.5 on their first visit to the ADC was used in this study. A sample of 
healthy controls meeting the relevant inclusion/exclusion for the study were also selected from 
ADC research participants. These individuals had a CDR of 0 and no evidence of impairment on 
testing.  
Measures 
 Uniform Data Set, Version 2 (UDS) neuropsychological test battery. The UDS 
neuropsychological test battery is a standardized collection of tests used at all ADCs across the 
country. Ten instruments assess attention, processing speed, executive function, memory, and 
language abilities (Weintraub et al., 2009). Measures and outcome scores are reported in Table 1. 
 Supplemental neuropsychological battery. An additional four tests were administered, 
consistent with the practice of the local ADC (see Table 1). These tests assess visuospatial 
reasoning (Block Design; Wechsler, 1987), attention/working memory (Letter Number 
Sequencing; Psychological Corporation, 1997), list learning/recall (Free and Cued Selective 
Reminding Test; FCSRT; Buschke, 1984; Grober & Buschke, 1987), and processing 
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speed/executive function (Stroop Test, Kaplan administration, with 45 sec time limit; Comalli, 
Wapner, & Werner, 1962; Mitrushina et al., 2005).  
 Geriatric Depression Scale – Short Form (GDS). The GDS is a 15-item instrument that 
asks individuals yes or no questions regarding how they have felt over the past week. It is a 
screening instrument for depression designed for use with older adult populations (Sheikh & 
Yesavage, 1986). Both the long and short forms have demonstrated adequate sensitivity and 
specificity. All study participants completed the GDS. 
Expanded Disability Status Scale (EDSS). The degree of MS patients’ neurological 
impairment was assessed by their neurologist (S. G. L.) using the EDSS scale. The scale 
describes physical disability and ranges from 0 (no neurological abnormality) to 10 (death from 
MS; Kurtzke, 1983). 
 Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) – Short 
Form. The IQCODE is a 16-item instrument that asks a patient’s friend or family member about 
changes in the individual’s cognition over the past 10 years (Jorm, 1994). The short form is 
strongly correlated with the long form, which has demonstrated adequate reliability, sensitivity, 
and specificity. The short form tends to be mildly but significantly correlated with the subject’s 
level of depression (r = 0.13; Jorm). The IQCODE was only collected from MS patients. The 
purpose was to identify a subset of patients that would most closely replicate the clinical scenario 
of a patient reporting cognitive concerns to their neurologist. In our effort to characterize the 
cognitive profile of MS patients, we were interested in whether a subset of patients with 
subjective complaints would differ from the collective sample and whether subjective complaints 





 MS patients were introduced to the study during the course of their regular appointment 
at the MS Clinic. All patients meeting inclusion and exclusion criteria were approached about 
participating in the study. If interest was expressed, a research assistant met with the patient to 
obtain written consent and schedule an appointment for a later testing session. Each session 
began with the administration of the UDS testing battery followed by the supplemental 
neuropsychological tests and GDS. The testing session lasted approximately 60 minutes. The 
IQCODE was completed either at the time of recruitment or, if the patient attended their clinic 
appointment alone, completed at a later date and mailed to the researchers. All participants 
signed informed consents. 
Statistical Analyses 
 Data analysis was conducted using IBM SPSS Version 23. Descriptive statistics are used 
to summarize demographic and study measures where appropriate. Neuropsychological test 
results are reported both as raw scores and scaled scores. The UDS battery was converted to z-
scores and then scaled scores using an online normative calculator based on a large descriptive 
study of nationwide UDS results (Shirk et al., 2011). Four additional normative samples were 
used to convert the raw scores in the supplemental neuropsychological battery to scaled scores 
(Ivnik et al., 1992; Ivnik et al., 1996; Ivnik et al., 1997; Psychological Corporation, 1987). All 
primary analyses were completed on raw scores; scaled scores were used to identify impairment. 
Group differences on neuropsychological test measures were assessed using one-way ANOVAs. 
All pairwise comparisons were Bonferroni-corrected. Only relevant comparisons (i.e., MS vs. 
healthy controls; MS vs. aMCI) are reported; differences between controls and aMCI patients are 
not discussed. Additionally, when significant differences in processing speed were found among 
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groups, speed on a simpler task (i.e., Trails A, Stroop Color Naming) was used to create 
covariate-adjusted scores for more complex tasks (i.e., Trails B, Stroop Interference). Finally, 
logistic regression was used to identify variables that best differentiated between MS and aMCI 
patients.  
 One-way ANOVAs were also used to explore subtype differences in demographic and 
neuropsychological test performance. Scaled scores were used to identify areas of impairment, 
and a repeated measures ANOVA compared rates of impairment across cognitive domains. 
Predictors of cognitive impairment were identified using multiple linear regression. Lastly, the 
significance of subjective cognitive concerns was also explored.  
Results 
Participants 
Sixty-four individuals with MS participated in the study, including 23 RRMS, 22 SPMS, 
and 19 PPMS patients. Additionally, data from 70 healthy controls and 58 individuals diagnosed 
with aMCI were extracted from a larger database based on inclusion/exclusion criteria for this 
study. The clinical and demographic characteristics of the participants are summarized in Table 
2. On average, individuals with MS had been diagnosed for 21.19 years (SD = 11.51). 
Significant variability was observed, however, with a range from two to 47 years since diagnosis. 
The median EDSS of the sample was 5.0 (range 1.0-8.0), which represents a moderate level of 
disability. Within the sample, 83% of MS patients were retired, and of those, half (50%) 
indicated retirement was due to disability. 
Across samples, there were a number of significant differences in demographic 
characteristics. The MS and aMCI patient groups had a significantly different distribution of men 
and women (χ2 (1) = 17.14, p < .001, Φ = .375) with women making up 77% of the MS sample 
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and only 40% of the aMCI group. There were no significant differences in sex distribution 
between the MS sample and healthy controls (81% female; χ2 (1) = 0.48, p = .489, Φ = .06). 
There was also a significant group difference in age (F(2, 189) = 26.43, p < .001, η2 = .22), such 
that individuals in the aMCI group were older than MS patients (p < .001, d = 1.15). Groups also 
differed significantly in their self-report of depressive symptoms on the GDS (F(2, 189) = 13.00, 
p < .001, η2 = .12). MS patients endorsed a greater number of statements than both healthy 
controls (p < .001, d = 0.93) and aMCI patients (p = .05, d = 0.07), indicating they experienced 
more mood symptoms than either of these other groups. All subsequent analyses were conducted 
with and without age and sex as covariates. If the covariates altered the findings, adjusted results 
are also reported.  
Between Group Analyses 
Comparisons of MS, aMCI, and healthy individuals’ performance on cognitive tests are 
reported in Table 3. MS patients differed significantly from healthy controls across tests of 
processing speed (Trails A, Digit-Symbol, Stroop Color Naming, and Stroop Word Reading), 
memory (Logical Memory Immediate, LM-I; Logical Memory Delayed, LM-II; FCSRT-Trial 1 
Free Recall, FCSRT-1F; and Total Free Recall, FCSRT-TF), verbal fluency (category fluency 
for animals and vegetables, CFA, CFV), and attention (Digit Span Forward, DSF) as well as on a 
cognitive screener (MMSE). The most robust differences, as indicated by effect sizes, were 
found on the Digit-Symbol test (d = 0.97) followed by performance on memory tasks (FCSRT-
TF: d = 0.92; LM-I and LM-II: d = 0.77); MS patients were significantly slower and recalled less 
information than healthy controls.  
When comparing the two patient groups to one another, MS patients differed 
significantly from aMCI patients on a cognitive screener (MMSE) and tests of memory (LM-I; 
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LM-II; FCSRT-1F; FCSRT-TF; FCSRT-Trial 1 Free and Cued Recall, FCSRT-1FC; FCSRT-
Accuracy, FCSRT-Acc.), language (Boston Naming Test, BNT; CFA; CFV), and executive 
function (Trails B). On all of these tasks, MS patients performed significantly better than aMCI 
patients. When corrected for age, the same general patterns are present, though group differences 
on verbal fluency tasks (CFA: p = .109, CFV: p = .187) and story memory (LM-I: p = .769, LM-
II: p = .275) were no longer significantly different. Similarly, when corrected for sex, the group 
differences on the story memory tasks were no longer significant (LM-I: p = .207, LM-II: p = 
.187). 
Based on the ANOVA findings, a logistic regression was conducted to further investigate 
the ability of cognitive variables to differentiate between MS and aMCI patients. Age, years of 
education, memory (FCSRT-1FC), and naming (BNT) were all significant predictors in the final 
model (χ2 (4) = 56.55, p < .001, Nagelkerke’s R2 = .50). MS patients were significantly younger, 
correctly named more pictures, and recalled fewer items from a list than aMCI patients. Overall, 
52 of 64 MS (81%) and 44 of 58 aMCI patients (76%) were correctly classified. The addition of 
executive function (i.e., Trails B), processing speed (i.e., Digit-Symbol, Stroop Color Naming), 
or other memory (i.e., Logical Memory) or language (i.e., verbal fluency) measures did not 
significantly improve classification. 
In addition to between-group comparisons using the full MS sample, comparisons among 
MS subtypes and other groups were also conducted. Relapsing remitting patients did not differ 
from healthy controls except in endorsing more items on the GDS (p < .001, d = 1.30). In 
contrast, the two groups of progressive patients showed a similar pattern of differences relative 
to controls, with poorer performance on story memory (LM-I: SPMS, p = .003, d = 0.94, PPMS, 
p = .005, d = 1.03; LM-II: SPMS, p = .006, d = 0.89, PPMS, p = .016, d = 0.91), free recall 
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(FCSRT-TF: SPMS, p = .002, d = 1.17, PPMS, p = .045, d = 1.04), processing speed tasks 
(Digit-Symbol: SPMS, p = .001, d = 1.08, PPMS, p <.001, d = 1.69; Stroop Color Naming: 
SPMS, p = .019, d = 0.83, PPMS, p = .028, d = 0.86; Stroop Word Reading: SPMS, p = .048, d = 
0.69; Trails A: PPMS, p < .001, d = 1.21), and a verbal fluency task (CFV: SPMS, p = .002, d = 
0.95, PPMS, p = .001, d = 1.02). Additionally, primary progressive patients reported 
significantly more depressive symptoms on the GDS than healthy controls (p = .002, d = 1.17). 
With respect to differences with the aMCI sample, the relapsing remitting patients differed 
across more measures than the progressive patients. Relapsing remitting patients were 
significantly younger than aMCI patients (p < .001, d = 1.45), so differences were considered 
with and without age as a covariate. Before correcting for age, significant differences were found 
on story memory (LM-I: p = .016, d = 0.75, LM-II: p = .048, d = 0.68), free recall (FCSRT-TF: 
p = .001, d = 0.82), verbal fluency (CFV: p = .002, d = 0.94), and the MMSE (p = .047, d = 
0.61). After age correction, the only variable remaining significant was total free recall. Primary 
progressive patients differed significantly from aMCI patients on the same measure (FCSRT-TF: 
p = .027, d = 0.64) as well as a measure of executive function (Trails B: p = .018, d = 0.11). On 
all measures, MS patients outperformed aMCI patients. However, secondary progressive patients 
did not significantly differ from aMCI patients on any measure except age (p < .001, d = 1.56). 
Analyses Among MS Subtypes 
In addition to group differences among MS patients, aMCI patients, and healthy controls, 
patterns of cognitive performance and impairment across the different subtypes of MS were 
explored. Demographic characteristics of the different subtypes are summarized in Table 4. 
There was a significant group difference across subtypes in age (F(2, 61) = 10.15, p < .001, η2 = 
.25), such that PPMS patients were significantly older than both RRMS (p = .001, d = 1.09) and 
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SPMS patients (p < .001, d = 1.23). The groups also differed significantly in EDSS score (F(2, 
61) = 10.32, p < .001, η2 = .25), with RRMS patients demonstrating less disability than SPMS (p 
= .006, d = 0.93) and PPMS patients (p < .001, d = 1.39).  All subsequent analyses were 
conducted with and without age and EDSS as a covariate. When adjusted for age, no significant 
group differences among MS subtypes were identified for any cognitive variable. Prior to being 
corrected for age, the only test for which there was a significant difference was that of Digit-
Symbol (F(2, 61) = 3.69, p = .031, η2 = .11), with PPMS patients demonstrating poorer 
performance than RRMS patients (p = .026, d = 0.41).  
In addition to analyzing raw scores, MS performance was also converted to age-corrected 
scaled scores, as described in the Method section. Scaled score means and standard deviations 
are reported by subtype and overall MS group in Table 5. Scaled scores were used to identify 
cognitive impairment at an individual level as well as to explore patterns in performance across 
different cognitive domains. First, test scores were coded as within normal limits or as impaired. 
Impairment was defined as a scaled score of 4 or lower, representing two standard deviations 
below the normative mean. Next, the number of tests with impaired performance was summed 
both within and across cognitive domains in order to classify an individual’s cognitive status as 
intact or impaired. Cognitive impairment, at an individual level, was defined as impaired 
performance on at least one test across two or more cognitive domains. Of the 64 MS patients in 
the study, 13 (20%) met these criteria. Across subtypes, four RRMS (17%), five SPMS (23%), 
and four PPMS (21%) patients met criteria for cognitive impairment.  
A repeated measures mixed ANOVA was conducted to explore differences in impairment 
across subtype and cognitive domain. The Greenhouse-Geisser correction was applied. There 
was no significant difference in impairment across cognitive domains among MS subtypes 
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(F(2,61) = 0.36, p = .701, η2 = .01). However, frequency of impaired test performance did differ 
significantly across cognitive domains (F(2.85,173.97) = 9.74, p < .001, η2 = .03). Pairwise 
comparisons revealed that performance on tests of processing speed was significantly worse than 
performance on tests of attention (p = .019, d = 0.49), executive function (p < .001, d = 0.53), 
language (p = .001, d = 0.64), and visuospatial processing (p < .001, d = 0.73). Performance on 
memory tasks was also significantly worse than performance on tests of language (p = .034, d = 
0.48) and visuospatial processing (p = .019, d = 0.58). See Figure 1 for a representation of the 
frequency of impairment across cognitive domain. 
A hierarchical regression analysis was conducted to investigate potential predictors of 
cognitive impairment. Specifically, the ability of three models to predict the sum of cognitive 
tests within an impaired range was evaluated. Model 1 consisted of demographic variables: age 
and years of education. Model 2 added clinical variables: length of diagnosis and EDSS score. 
Model 3 added cognitive and mood screeners and questionnaires: GDS, IQCODE, and MMSE 
scores. A bootstrapped Model 3 predicted the largest amount of variance (r2 = .39; see Table 6). 
Individual variables contributing significantly to the model included length of diagnosis (p = 
.038) and EDSS score (p = .039).  
Informant report of perceived cognitive decline as measured on the IQCODE was further 
investigated as a potential predictor of cognitive impairment. Of the 51 patients with completed 
forms, 13 (26%) met criteria for cognitive impairment based on the cut score described in Jorm 
(1994). However, subjective report of cognitive change was not significantly related to other 
relevant variables, such as age, education, disease duration, EDSS, or MMSE, based on 
Spearman correlations. Additionally, a chi-square analysis comparing classification rates (i.e., 
impaired or not impaired) across the two definitional approaches (i.e., informant report or 
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cognitive performance) found significant differences (χ2 (1) = 7.80, p = .005, Φ = .391), 
indicating that informant report of cognitive concerns was not consistent with the results of 
cognitive testing. Only 46% of individuals labeled as impaired based on the IQCODE were also 
identified as impaired based on cognitive performance. Sixty percent of MS patients classified as 
impaired based on test performance were labeled as impaired based on informant report. This 
inconsistency indicates that subjective report of cognitive decline is not meaningfully connected 
to cognitive impairment as identified on objective tests.   
Discussion 
Memory Performance Relative to Healthy Controls  
Comparisons of cognitive performance among MS, aMCI, and healthy samples were 
largely consistent with our hypotheses and findings previously reported in the literature. MS 
patients performed more poorly than healthy controls most consistently and robustly across 
measures of processing speed and memory. The pattern of memory performance is also 
consistent with findings in the broader MS population. Patients demonstrated poor free recall of 
a story (i.e., Logical Memory) as well as a series of items presented in a visually- and orally-
mediated controlled learning procedure (i.e., Free and Cued Selective Reminding Test). Cued 
recall improved patients’ performance such that overall accuracy was comparable with that of 
healthy controls. Additionally, MS patients retained information over time without a greater rate 
of forgetting than healthy individuals, as demonstrated by the retention rate from immediate to 
delayed recall of a story.  
There are two competing explanations for the dissociation between free recall and 
recognition performance typically observed in MS patients. Historically, this this pattern of 
performance has been characterized as a retrieval deficit (e.g., Rao, Leo, St. Aubin-Faubert, 
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1989). Others, however, have suggested that poor recall can be attributed to an acquisition deficit 
instead (e.g., DeLuca, Barbieri-Berger, & Johnson, 1994). When MS patients and healthy 
controls are both trained to a criterion (i.e., 100% immediate recall on two consecutive trials), 
MS patients require more trials to reach criterion; subsequently, though, delayed free recall 
becomes equivalent between groups (DeLuca et al., 1994, DeLuca et al., 1998). Thus, when 
initial learning is controlled, an apparent deficit in memory is attenuated. Clinically-oriented 
studies, such as the present one, are not suited to adequately test these hypotheses, which require 
modification of standardized administration procedures. Thus, either the retrieval or the 
acquisition hypothesis may account for the pattern of performance observed in this study. 
Further, other factors may also have contributed to MS patient’s performance on memory 
tasks. For example, slowed processing speed might explain lower free recall scores on the 
FCSRT. The free recall portion of each trial was limited to 90 seconds or ended after a 15-second 
interval with no response. If MS patients were significantly slower to respond, this may have 
depressed their free recall scores relative to healthy controls. A second consideration involves 
performance on cued recall tasks. Both MS patients and healthy controls, at a group level, 
approached perfect performance (i.e., 99% accuracy) on cued recall tasks, indicating the 
presence of ceiling effects. It may be that differences exist between MS and healthy controls that 
were not observed because the task was too simple. Overall, while the MS patients’ pattern of 
performance on memory tasks is consistent with that described in the literature, multiple factors 
must be considered when interpreting the implications of their performance.  
Cognitive Similarities and Differences with an aMCI Sample 
Perspectives on cognitive performance can also be informed by comparing different 
patient samples to one another. In this study, comparisons were made between MS and aMCI 
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patients. This comparison represents a possible differential that clinicians might realistically 
encounter. Therefore, it is helpful to consider variables that distinguish these two groups. 
Importantly, there was no measure on which MS patients performed significantly worse than 
individuals with aMCI. Performance was similar on measures of processing speed and attention. 
Consistent with hypotheses, aMCI patients differed the most from MS patients on tasks assessing 
memory and language. Specifically, while MS patients demonstrated significantly poorer free 
recall than healthy controls, aMCI patients’ recall was even worse. Further, in contrast to the MS 
sample, the performance of aMCI patients does not improve when cues are provided, suggesting 
that information is not available for retrieval and is, therefore, not being adequately encoded or 
stored. These results are largely consistent with the one other study comparing MS and aMCI 
samples (Müller et al., 2013). However, we found more group differences than reported by 
Müller and colleagues. In their study, groups only differed on a recognition task. One possible 
explanation for this difference is that only SPMS patients were included in the Müller et al. 
study. When we analyzed our data at the subtype level, SPMS patients did not significantly differ 
from aMCI patients on any measure. These findings suggest that, while the cognitive profile of 
aMCI patients is more severe than that of MS patients, there are also a number of commonalities, 
at a group level, between these samples.  
Impairment within the MS Sample 
 In addition to differences relative to healthy controls or aMCI patients, patterns of 
cognitive performance and impairment were also explored within the MS sample. The reported 
rate of 20% in this study is lower than what is typically reported in the literature. The most 
consistently cited range of cognitive impairment is 40% to 70% (Chiaravalloti & DeLuca, 2008). 
The only other study with older adult patients to report a rate of impairment was also much 
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higher (48%) than the present study (Smestad et al., 2010). One consideration for these 
differences is that the definition of impairment in the present study was relatively stringent. We 
required performance two standard deviations below a normative mean on at least one test in two 
different cognitive domains. Smestad and colleagues had slightly more liberal criteria with 
impairment defined at 1.5 standard deviations below a mean. A recent review reported on the 
effect of variable definitions of cognitive impairment across MS studies and demonstrated that 
definitions can dramatically alter reported rates of impairment (Fischer et al., 2014). Because our 
definition was based on standardized scaled scores as reported in available normative samples, it 
was not possible to consider fractional standard deviations below the mean; the scaled scores 
could only be translated into whole integers.  Another possible explanation for the lower rate of 
impairment is that, rather than being a function of definitional factors, it reflects a characteristic 
of this sample. In particular, there is a high level of educational attainment within the MS sample 
(M = 15.34, SD = 2.33). Years of education is thought to correspond to cognitive reserve. 
Multiple studies within MS have demonstrated that cognitive reserve can protect from or reduce 
the consequences of cognitive decline and impairment (DeLuca et al., 2014; Feinstein, Lapshin, 
O’Connor, & Lanctôt, 2013).  
 While the overall rate of impairment was lower than anticipated, the pattern of cognitive 
domains affected is very consistent with the broader literature. The domain demonstrating the 
highest rate of impairment was processing speed, with 36% of MS patients demonstrating 
impaired performance on at least one measure of processing speed. The second domain in which 
patients demonstrated significant impairment was memory (25%). The percentages of the sample 
demonstrating impairment on the remaining tasks were all low and did not differ significantly 
from one another (attention, 16%; executive function, 11%; language, 11%; visuospatial 
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processing, 6%). This pattern of deficits is consistent with multiple reviews of cognition in MS 
(i.e., Bobholz & Rao, 2003; Chiaravalloti & DeLuca, 2008; Guimarães & Sá, 2012).  
 Patterns across subtypes observed in the present study are also generally consistent with 
the literature. Direct comparisons of subtypes with one another did not find any significant 
differences in test performance or rates of impairment; however, comparisons with external 
groups illustrate some important differences among subtypes. There appear to be separate 
patterns of performance for patients with a relapsing remitting versus progressive disease 
courses. RRMS patients showed very few differences relative to healthy controls, while 
progressive patients differed significantly. In contrast, relative to an aMCI sample, individuals 
with a progressive disease course showed minimal differences, while RRMS patients differed 
across a greater number of measures. The lack of differentiation between RRMS patients and 
healthy controls is somewhat surprising. Most studies report evidence of relative impairment 
across all subtypes and severity levels of disease course, particularly on tasks of processing 
speed (Denney, Sworowski, & Lynch, 2005; De Sonneville, et al., 2002; Zakzanis, 2000). It may 
be that this patient group–individuals whose disease course has remained stable and relatively 
mild for decades–represents some of the healthiest individuals with MS. So much so, that older 
adult RRMS patients may appear as cognitively intact as their healthy same-age peers.  
 Differentiating between the cognitive profiles of the two progressive subtypes is 
somewhat challenging. Again, these groups do not significantly different from one another on 
any direct comparison across raw or normed scores or rate of impairment (SPMS, 23%, PPMS, 
22%). Similarly, their performance relative to healthy controls and comparable with one another. 
There are some relative differences when compared to the aMCI sample. PPMS patients differ 
significantly from aMCI patients on two measures, one of memory and one of executive 
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function, while SPMS patients do not differ significantly on any measure. The literature on 
differences in cognitive impairment between SPMS and PPMS patients is inconclusive. The 
SPMS disease course is generally thought to be associated with greater cognitive impairment 
(Chiaravalloti & DeLuca, 2008). Reported rates of impairment are typically between 50% and 
70% (Cáceres, Vanotti, Rao, & RECONEM Workgroup, 2011; Comi et al. 1995; Foong et al., 
2000; Smestad et al., 2010). However, it is challenging to compare these findings to rates of 
impairment in PPMS patients because estimates vary so dramatically (i.e., 7% in Comi et al. 
versus 100% in Cáceres et al.). The variability is probably attributable to very small sample sizes 
(e.g., n < 10), which quickly distort percentages. Our findings are most consistent with those 
studies reporting little difference between progressive subtypes (Camp et al., 1991, Smested et 
al.). However, it should also be noted that a limitation of our results is the relatively small sample 
sizes within subtypes (SPMS, n = 22; PPMS, n = 19) and the corresponding reduction in power 
to detect significant group differences.  
In general, knowing a patients’ disease course, particularly whether it is relapsing 
remitting or progressive in nature, will inform predictions of cognitive performance. Other 
factors found to be significantly associated with cognitive impairment in this study included 
EDSS scores and disease duration. EDSS has been found to have mild to moderate associations 
with cognitive impairment, though the relationship between physical and cognitive disability is 
typically weaker than what might be assumed (Chiaravalloti & DeLuca, 2008; Lynch, Parmenter, 
& Denney, 2005). The second variable found to be associated with cognitive impairment in this 
study was that of disease duration, or, more specifically, years since diagnosis. This is not 
consistent with the broader literature, though our findings do replicate a handful of more recent 
studies with older patient samples and wider ranges of disease durations. Previously, disease 
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duration has not, in general, been associated with cognitive impairment. Impairment can be 
found at all durations, even in patients with clinically isolated syndrome, which is considered by 
some to be a prodromal stage of MS (DeLuca et al., 2014). Additionally, disease duration does 
not predict performance on neuropsychological test measures (Beatty et al., 1990). However, a 
recent large scale study investigating 1,500 patients with a broad range of disease durations (1 to 
55 years) reported significant associations between disease duration and cognitive impairment 
across various cognitive domains (Achiron et al., 2014). Further, in a specific sample of older 
adults also demonstrating a wide range of disease duration (i.e., 12-53 years), Smestad and 
colleagues (2010) similarly found a significant relationship between age of onset and cognitive 
impairment. These studies suggest that perhaps there has been a restricted range of disease 
duration in prior studies with younger patients, and this has affected the conclusions reached. 
Evidence from the present study and other recent work with broad ranges of disease duration 
suggests the relationship between cognitive impairment and disease duration warrants further 
consideration.  
Conclusions 
This study expands upon the existing literature in multiple ways. It is one of the largest 
samples of older adult MS patients and it is the oldest sample, on average, to be described in the 
literature. At a subtype level, it comprises the largest sample of older adult primary progressive 
patients to be characterized. Additional strengths of the study are the inclusion of multiple 
disease courses and the wide range of disease durations. Some of the conclusions are limited by 
small sample sizes within the MS subtypes. Additionally, while the range in disease duration is a 
strength, it is also important to recognize that this variable was determined via self-reported time 
since diagnosis, which may differ from the actual time of disease onset. Definitions of cognitive 
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impairment are variable in the literature. Our definition is one of the more stringent; therefore, 
estimates of impairment are likely more conservative than in other studies. Further, impairment 
was defined based on normative scores. Multiple normative samples were needed to calculate 
scaled scores for all the measures in our battery, which is not ideal. Finally, a significant age 
difference between MS and aMCI patients is problematic. It would have been preferable to 
create equivalency on this variable at the recruitment stage rather than correcting for age through 
statistical means.  
 Overall, this study adds to our knowledge of cognitive abilities in older adult MS 
patients. Similar to patterns seen in younger adults, processing speed and memory functions 
remain the most frequently impaired cognitive abilities. In contrast to younger samples, disease 
duration emerged as a relevant predictor of cognitive impairment. Comparisons with another 
clinical sample – aMCI patients – reveal a high degree of overlap between these two patient 
groups. This demonstrates the challenge clinicians face when trying to understand the etiology of 
cognitive changes in their older adult MS patients. As MS patients age, there will be a greater 
need to consider comorbid conditions that may contribute to cognitive complaints. Finally, while 
much can be learned from cross-sectional studies such as the present one, there is also a 
substantial need for long-term, controlled longitudinal studies on cognitive change in MS that 
follow patients into older adulthood. As several of the participants in this study observed at the 
end of their testing session, “Well, what you really need to do is come test me again in a few 
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Neuropsychological outcome measures organized by cognitive domain 
Cognitive Domain Test Measure Abbrev. Outcome Scores 
Screener Mini-Mental State Examination  MMSE Total score 
Attention Digit Span Forward  DSF Total correct 
 Digit Span Backward  DSB Total correct 
 Letter Number Sequencing a  LNS Total correct 
Processing Speed Digit Symbol  D-S Total correct 
 Trail Making Test, Part A  TMA Completion time 
 Stroop Test, Color Naming a -- Total correct 
 Stroop Test, Word Reading a -- Total correct 
Executive 
function 
Trail Making Test, Part B TMB Completion time 
 Stroop Test, Interference a -- Total correct 
Memory Logical Memory, Story A LM-I 
LM-II 
LM-Ret 
Immediate recall total 
correct 
Delayed recall total 
correct 
Percent retained 
 Free & Cued Selective 





Trial 1 free recall 
Trial 1 free & cued 
recall 
Total free recall 
Total accuracy 
Language Semantic fluency – animals, 
vegetables 
CFA, CFV Total correct 
 Boston Naming Test (30 items) BNT Total correct 
Visuospatial Block Design a BD Total points 
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